Carcinosarcomas (Malignant Mixed Müllerian Tumor) of the Uterus: Advances in Elucidation of Biologic and Clinical Characteristics

Vaidya AP, Horowitz NS, Oliva E et al.. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol 2006;103:684–687.

VaidyaAPHorowitzNSOlivaE. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol 2006;103:684–687. )| false
• Search Google Scholar
• Export Citation

Wada H, Enomoto T, Fujita M et al.. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997;57:5379–5385.

WadaHEnomotoTFujitaM. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997;57:5379–5385. )| false
• Search Google Scholar
• Export Citation

Abeln EC, Smit VT, Wessels JW et al.. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol 1997;183:424–431.

AbelnECSmitVTWesselsJW. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol 1997;183:424–431. )| false
• Search Google Scholar
• Export Citation

Bansal N, Herzog TJ, Seshan VE et al.. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstetrics and Gynecology 2008;112:64–70.

BansalNHerzogTJSeshanVE. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstetrics and Gynecology 2008;112:64–70. )| false
• Search Google Scholar
• Export Citation

Di Cristofano E, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol Mech Dis 2007;2:57–85.

Di CristofanoEEllensonLH. Endometrial carcinoma. Annu Rev Pathol Mech Dis 2007;2:57–85. )| false
• Search Google Scholar
• Export Citation

Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995;19:666–674.

SreenanJJHartWR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995;19:666–674. )| false
• Search Google Scholar
• Export Citation

Jin Z, Ogata S, Tamura G et al.. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol 2003;22:368–373.

JinZOgataSTamuraG. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol 2003;22:368–373. )| false
• Search Google Scholar
• Export Citation

Barnholtz-Sloan JS, Morris R, Malone JM Jr, Munkarah AR. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol 2004;93:506–512.

Barnholtz-SloanJSMorrisRMaloneJM JrMunkarahAR. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol 2004;93:506–512. )| false
• Search Google Scholar
• Export Citation

Lim BJ, Kim JW, Yang WI, Cho NH. Malignant mixed mullerian tumor of fallopian tube with multiple distinct heterologous components. Int J Gynecol Cancer 2004;14:690–693.

LimBJKimJWYangWIChoNH. Malignant mixed mullerian tumor of fallopian tube with multiple distinct heterologous components. Int J Gynecol Cancer 2004;14:690–693. )| false
• Search Google Scholar
• Export Citation

Sebenik M, Yan Z, Khalbuss WE, Mittal K. Malignant mixed mullerian tumor of the vagina: case report with review of the literature, immunohistochemical study, and evaluation for human papilloma virus. Hum Pathol 2007;38:1282–1288.

SebenikMYanZKhalbussWEMittalK. Malignant mixed mullerian tumor of the vagina: case report with review of the literature, immunohistochemical study, and evaluation for human papilloma virus. Hum Pathol 2007;38:1282–1288. )| false
• Search Google Scholar
• Export Citation

Robboy SJ, Mutter GL, Prat J et al.., eds. Robboy’s Pathology of the Female Reproductive Tract. 2nd ed. China: Churchill Livingstone Elsevier; 2009.

RobboySJMutterGLPratJ., eds. Robboy’s Pathology of the Female Reproductive Tract. 2nd ed. China: Churchill Livingstone Elsevier; 2009. )| false
• Search Google Scholar
• Export Citation

Teo SY, Babagbemi KT, Peters HE, Mortele KJ. Primary malignant mixed mullerian tumor of the uterus: findings on sonography, CT, and gadolinium-enhanced MRI. AJR Am J Roentgenol 2008;191:278–283.

TeoSYBabagbemiKTPetersHEMorteleKJ. Primary malignant mixed mullerian tumor of the uterus: findings on sonography, CT, and gadolinium-enhanced MRI. AJR Am J Roentgenol 2008;191:278–283. )| false
• Search Google Scholar
• Export Citation

Zelmanowicz A, Hildesheim A, Sherman ME et al.. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998;69:253–257.

ZelmanowiczAHildesheimAShermanME. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998;69:253–257. )| false
• Search Google Scholar
• Export Citation

McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687–690.

McCluggageWG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687–690. )| false
• Search Google Scholar
• Export Citation

Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004;96:70–74.

CurtisREFreedmanDMShermanMEFraumeniJF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004;96:70–74. )| false
• Search Google Scholar
• Export Citation

Cotran RS, Kumar V, Collins T, eds. Robbins Pathologic Basis of Disease. 6th ed. Philadelphia: W.B. Saunders Company; 1999.

CotranRSKumarVCollinsT, eds. Robbins Pathologic Basis of Disease. 6th ed. Philadelphia: W.B. Saunders Company; 1999. )| false
• Search Google Scholar
• Export Citation

Crum CP, Lee KR, eds. Diagnostic Gynecologic and Obstetric Pathology. China: Elsevier Saunders; 2006.

CrumCPLeeKR, eds. Diagnostic Gynecologic and Obstetric Pathology. China: Elsevier Saunders; 2006. )| false
• Search Google Scholar
• Export Citation

Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990;14:317–328.

BittermanPChunBKurmanRJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990;14:317–328. )| false
• Search Google Scholar
• Export Citation

Chung MT, Mukai K, Teshima S et al.. Expression of various antigens by different components of uterine mixed mullerian tumors. An immunohistochemical study. Acta Pathol Jpn 1988;38:35–45.

ChungMTMukaiKTeshimaS. Expression of various antigens by different components of uterine mixed mullerian tumors. An immunohistochemical study. Acta Pathol Jpn 1988;38:35–45. )| false
• Search Google Scholar
• Export Citation

Dupont J, Wang X, Marshall DS et al.. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 2004;94:449–455.

DupontJWangXMarshallDS. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 2004;94:449–455. )| false
• Search Google Scholar
• Export Citation

Kounelis S, Jones MW, Papadaki H et al.. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29:82–87.

KounelisSJonesMWPapadakiH. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29:82–87. )| false
• Search Google Scholar
• Export Citation

Schipf A, Mayr D, Kirchner T, Diebold J. Molecular genetic aberrations of ovarian and uterine carcinosarcomas—a CGH and FISH study. Virchows Arch 2008;452:259–268.

SchipfAMayrDKirchnerTDieboldJ. Molecular genetic aberrations of ovarian and uterine carcinosarcomas—a CGH and FISH study. Virchows Arch 2008;452:259–268. )| false
• Search Google Scholar
• Export Citation

Silverberg SG, Major FJ, Blessing JA et al.. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1–19.

SilverbergSGMajorFJBlessingJA. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1–19. )| false
• Search Google Scholar
• Export Citation

Amant F, Vloeberghs V, Woestenborghs H et al.. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol 2003;90:372–377.

AmantFVloeberghsVWoestenborghsH. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol 2003;90:372–377. )| false
• Search Google Scholar
• Export Citation

Inthasorn P, Carter J, Valmadre S et al.. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer 2002;12:348–353.

InthasornPCarterJValmadreS. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer 2002;12:348–353. )| false
• Search Google Scholar
• Export Citation

Wolfson AH, Brady MF, Rocereto T et al.. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177–185.

WolfsonAHBradyMFRoceretoT. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177–185. )| false
• Search Google Scholar
• Export Citation

Cicin I, Saip P, Eralp Y et al.. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008;108:136–140.

CicinISaipPEralpY. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008;108:136–140. )| false
• Search Google Scholar
• Export Citation

Homesley HD, Filiaci V, Markman M et al.. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:526–531.

HomesleyHDFiliaciVMarkmanM. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:526–531. )| false
• Search Google Scholar
• Export Citation

Silasi DA, Illuzzi JL, Kelly MG et al.. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008;18:22–29.

SilasiDAIlluzziJLKellyMG. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008;18:22–29. )| false
• Search Google Scholar
• Export Citation

Sutton G, Brunetto VL, Kilgore L et al.. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gyn Oncol 2000;79:147–153.

SuttonGBrunettoVLKilgoreL. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gyn Oncol 2000;79:147–153. )| false
• Search Google Scholar
• Export Citation

Schulten HJ, Gunawan B, Enders C et al.. Overrepresentation of 8q in carcinosarcomas and endometrial adenocarcinomas. Am J Clin Pathol 2004;122:546–551.

SchultenHJGunawanBEndersC. Overrepresentation of 8q in carcinosarcomas and endometrial adenocarcinomas. Am J Clin Pathol 2004;122:546–551. )| false
• Search Google Scholar
• Export Citation

Jeffers MD, Richmond JA, Macaulay EM. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas. Mod Pathol 1995;8:701–704.

JeffersMDRichmondJAMacaulayEM. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas. Mod Pathol 1995;8:701–704. )| false
• Search Google Scholar
• Export Citation

Fujii H, Yoshida M, Gong ZX et al.. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 2000;60:114–120.

FujiiHYoshidaMGongZX. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 2000;60:114–120. )| false
• Search Google Scholar
• Export Citation

Seidman JD, Chauhan S. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas. Int J Gynecol Pathol 2003;22:75–82.

SeidmanJDChauhanS. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas. Int J Gynecol Pathol 2003;22:75–82. )| false
• Search Google Scholar
• Export Citation